Equities research analysts at BMO Capital Markets boosted their price objective on shares of Genomic Health (NASDAQ:GHDX) from $18.00 to $20.00 in a research note issued to investors on Thursday, AnalystRatings.Net reports. The firm currently has an “underperform” rating on the stock. BMO Capital Markets’ price objective suggests a potential downside of 40.10% from the stock’s previous close.
Genomic Health (NASDAQ:GHDX) traded up 1.43% during mid-day trading on Thursday, hitting $33.39. The stock had a trading volume of 324,757 shares. Genomic Health has a 52 week low of $25.25 and a 52 week high of $38.99. The stock has a 50-day moving average of $30.56 and a 200-day moving average of $33.10. The company has a market cap of $1.022 billion and a P/E ratio of 557.97.
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, November 5th. The company reported $0.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.04) by $0.06. The company had revenue of $65.99 million for the quarter, compared to the consensus estimate of $64.98 million. During the same quarter in the prior year, the company posted $0.11 earnings per share. The company’s quarterly revenue was up 12.6% on a year-over-year basis. Analysts expect that Genomic Health will post $-0.10 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity cut their price target on shares of Genomic Health from $35.00 to $33.00 in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Separately, analysts at William Blair upgraded shares of Genomic Health from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday. Finally, analysts at Bank of America Corp. downgraded shares of Genomic Health from a “neutral” rating to an “underperform” rating in a research note to investors on Tuesday, October 1st. They now have a $33.00 price target on the stock, down previously from $36.00. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. Genomic Health currently has an average rating of “Hold” and an average price target of $33.80.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.